Last reviewed · How we verify
Glycemic Rescue
Glycemic Rescue is a glucose-stabilizing agent designed to rapidly restore blood glucose levels in acute hypoglycemic episodes.
Glycemic Rescue is a glucose-stabilizing agent designed to rapidly restore blood glucose levels in acute hypoglycemic episodes. Used for Acute severe hypoglycemia in diabetic patients.
At a glance
| Generic name | Glycemic Rescue |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
The drug works by stimulating hepatic glucose production and enhancing glucose mobilization from endogenous stores. It is intended for emergency use in severe hypoglycemia when oral glucose administration is not feasible or effective, particularly in diabetic patients experiencing acute glycemic crises.
Approved indications
- Acute severe hypoglycemia in diabetic patients
Common side effects
Key clinical trials
- Glycemic Targets During CPB in Elderly Diabetes (NA)
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes (PHASE4)
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) (PHASE3)
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (PHASE3)
- A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289) (PHASE3)
- Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients (NA)
- Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly (PHASE4)
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |